Literature DB >> 22127592

Advances in pediatric rhabdomyosarcoma characterization and disease model development.

D O'Brien1, A G Jacob, S J Qualman, D S Chandler.   

Abstract

Rhabdomyosarcoma (RMS), a form of soft tissue sarcoma, is one of the most common pediatric malignancies. A complex disease with at least three different subtypes, it is characterized by perturbations in a number of signaling pathways and genetic abnormalities. Extensive clinical studies have helped classify these tumors into high and low risk groups to facilitate different treatment regimens. Research into the etiology of the disease has helped uncover numerous potential therapeutic intervention points which can be tested on various animal models of RMS; both genetically modified models and tumor xenograft models. Taken together, there has been a marked increase in the survival rate of RMS patients but the highly invasive, metastatic forms of the disease continue to baffle researchers. This review aims to highlight and summarize some of the most important developments in characterization and in vivo model generation for RMS research, in the last few decades.

Entities:  

Mesh:

Year:  2012        PMID: 22127592      PMCID: PMC3922709          DOI: 10.14670/HH-27.13

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  69 in total

1.  Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms.

Authors:  R Stad; N A Little; D P Xirodimas; R Frenk; A J van der Eb; D P Lane; M K Saville; A G Jochemsen
Journal:  EMBO Rep       Date:  2001-10-17       Impact factor: 8.807

2.  Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes.

Authors:  Julia A Bridge; Jian Liu; Stephen J Qualman; Ron Suijkerbuijk; Gail Wenger; Ji Zhang; Xiaoying Wan; K Scott Baker; Poul Sorensen; Frederic G Barr
Journal:  Genes Chromosomes Cancer       Date:  2002-03       Impact factor: 5.006

3.  Association of alveolar rhabdomyosarcoma with the Beckwith-Wiedemann syndrome.

Authors:  A C Smith; J A Squire; P Thorner; M Zielenska; C Shuman; R Grant; D Chitayat; J L Nishikawa; R Weksberg
Journal:  Pediatr Dev Pathol       Date:  2001 Nov-Dec

4.  Amplification of the MDM2 gene, but not expression of splice variants of MDM2 MRNA, is associated with prognosis in soft tissue sarcoma.

Authors:  F Bartel; A Meye; P Würl; M Kappler; M Bache; C Lautenschläger; U Grünbaum; H Schmidt; H Taubert
Journal:  Int J Cancer       Date:  2001-05-20       Impact factor: 7.396

5.  PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.

Authors:  Poul H B Sorensen; James C Lynch; Stephen J Qualman; Roberto Tirabosco; Jerian F Lim; Harold M Maurer; Julia A Bridge; William M Crist; Timothy J Triche; Frederic G Barr
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

6.  An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2.

Authors:  S C Evans; M Viswanathan; J D Grier; M Narayana; A K El-Naggar; G Lozano
Journal:  Oncogene       Date:  2001-07-05       Impact factor: 9.867

7.  Novel mdm2 splice variants identified in pediatric rhabdomyosarcoma tumors and cell lines.

Authors:  F Bartel; A C Taylor; H Taubert; L C Harris
Journal:  Oncol Res       Date:  2001       Impact factor: 5.574

8.  Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3.

Authors:  M J Anderson; G D Shelton; W K Cavenee; K C Arden
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

9.  Pax3-FKHR knock-in mice show developmental aberrations but do not develop tumors.

Authors:  Irina Lagutina; Simon J Conway; Jack Sublett; Gerard C Grosveld
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

Review 10.  Molecular pathogenesis of rhabdomyosarcoma.

Authors:  Shujuan J Xia; Joseph G Pressey; Frederic G Barr
Journal:  Cancer Biol Ther       Date:  2002 Mar-Apr       Impact factor: 4.742

View more
  11 in total

Review 1.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

2.  miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR.

Authors:  M Y Balkhi; Mumtaz Y Balkhi; O Hans Iwenofu; Nadine Bakkar; Katherine J Ladner; Dawn S Chandler; Peter J Houghton; Cheryl A London; William Kraybill; Danilo Perrotti; Carlo M Croce; Charles Keller; Denis C Guttridge
Journal:  Sci Signal       Date:  2013-07-30       Impact factor: 8.192

3.  DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation.

Authors:  Francesca Megiorni; Simona Camero; Simona Ceccarelli; Heather P McDowell; Olga Mannarino; Francesco Marampon; Barry Pizer; Rajeev Shukla; Antonio Pizzuti; Cinzia Marchese; Anna Clerico; Carlo Dominici
Journal:  Oncotarget       Date:  2016-11-29

4.  DMD transcripts in CRL-2061 rhabdomyosarcoma cells show high levels of intron retention by intron-specific PCR amplification.

Authors:  Emma Tabe Eko Niba; Ryo Yamanaka; Abdul Qawee Mahyoob Rani; Hiroyuki Awano; Masaaki Matsumoto; Hisahide Nishio; Masafumi Matsuo
Journal:  Cancer Cell Int       Date:  2017-05-23       Impact factor: 5.722

5.  The histone methyltransferase SUV39H1 suppresses embryonal rhabdomyosarcoma formation in zebrafish.

Authors:  Colleen E Albacker; Narie Y Storer; Erin M Langdon; Anthony Dibiase; Yi Zhou; David M Langenau; Leonard I Zon
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

6.  Targeting PI3K/Akt represses Hypoxia inducible factor-1α activation and sensitizes Rhabdomyosarcoma and Ewing's sarcoma cells for apoptosis.

Authors:  Mehtap Kilic-Eren; Tulin Boylu; Vedrana Tabor
Journal:  Cancer Cell Int       Date:  2013-04-16       Impact factor: 5.722

7.  Cell-based small-molecule compound screen identifies fenretinide as potential therapeutic for translocation-positive rhabdomyosarcoma.

Authors:  David Herrero Martín; Aleksandar Boro; Beat W Schäfer
Journal:  PLoS One       Date:  2013-01-25       Impact factor: 3.240

8.  Distinct malignant behaviors of mouse myogenic tumors induced by different oncogenetic lesions.

Authors:  Simone Hettmer; Roderick T Bronson; Amy J Wagers
Journal:  Front Oncol       Date:  2015-02-24       Impact factor: 6.244

9.  A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo.

Authors:  D F Comiskey; A G Jacob; B L Sanford; M Montes; A K Goodwin; H Steiner; E Matsa; A S Tapia-Santos; T W Bebee; J Grieves; K La Perle; P Boyaka; D S Chandler
Journal:  Oncogene       Date:  2017-09-11       Impact factor: 9.867

Review 10.  Surgical Interventions for Advanced Parameningeal Rhabdomyosarcoma of Children and Adolescents.

Authors:  Paul J Choi; Joe Iwanaga; R Shane Tubbs; Emre Yilmaz
Journal:  Cureus       Date:  2018-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.